Climb Bio
CLYM

Climb Bio (CLYM) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
HC Wainwright & Co.MaintainedBuy$24.00 from $20.00Aug 24, 2026
WedbushMaintainedOutperform$20.00Aug 19, 2026
Truist SecuritiesMaintainedBuy$25.00 from $17.00Aug 7, 2026
WedbushMaintainedOutperform$20.00 from $17.00Jul 27, 2026
HC Wainwright & Co.MaintainedBuy$20.00Jun 24, 2026
WedbushMaintainedOutperform$17.00Jun 12, 2026
BTIGMaintainedBuy$20.00 from $19.00Jun 11, 2026
BTIGMaintainedBuy$19.00Jun 8, 2026
GuggenheimInitiated CoverageBuy$35.00Jun 8, 2026
HC Wainwright & Co.MaintainedBuy$20.00 from $15.00May 12, 2026
WedbushMaintainedOutperform$17.00 from $15.00May 8, 2026
BTIGMaintainedBuy$19.00 from $8.00May 6, 2026
Chardan CapitalInitiated CoverageBuy$22.00May 5, 2026
OppenheimerMaintainedOutperform$18.00 from $10.00Apr 21, 2026
MizuhoInitiated CoverageOutperform$18.00Apr 15, 2026
BTIGMaintainedBuy$8.00Apr 8, 2026
B. Riley SecuritiesInitiated CoverageBuy$26.00Mar 24, 2026
Truist SecuritiesInitiated CoverageBuy$17.00Mar 18, 2026
Raymond JamesInitiated CoverageStrong Buy$25.00Mar 11, 2026
HC Wainwright & Co.MaintainedBuy$15.00 from $11.00Mar 10, 2026

Frequently asked questions

  • What is the latest analyst rating on CLYM?

    On Aug 24, 2026, HC Wainwright & Co. maintained Climb Bio at Buy with a price target of $24.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.